

**Supplementary Table 3**  
**R&D costs for clinical development of existing candidates**

	Number of existing candidates per phase			Expected clinical development costs (\$M, 2008)	
	Preclinical	Phase I	Phase II	FY09	Total*
<b>Small molecules</b>	10	2	-	329	1,349
<b>Vaccines</b>	8	6	1	397	2,229
<b>Biological therapeutics</b>	3	2	-	92	519
<b>Total</b>	21	10	1	817	4,097

\* Total costs represent development costs accrued until success or failure of candidates.